ARCH Venture Partners Healthcare News

This is selected healthcare news for ARCH Venture Partners, which is filed under Capital Firms. There are 374 news items for this page. ARCH Venture Partners is occasionally combined with Volastra Therapeutics, Arivale and Juno Therapeutics in news items. A press release filter page is also available for ARCH Venture Partners.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/5/2022 SonoThera‚Ñ¢ Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development
... will support the continued development of SonoThera's ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines. Lead investor ARCH Venture Partners was joined by investors Illumina Ventures, Johnson & Johnson Innovation ‚Ai JJDC, Inc., Vertex Ventures HC, and Medical Excellence Capital. Also participating in ...
Business Wire
12/1/2022 Stock Market | FinancialContent Business Page
... developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing. The financing round was supported by existing investors, including ARCH Venture Partners, Rosetta Capital, Lightstone Ventures, Google Ventures, Cambridge Innovation Capital, and Evotec. The Company intends to use the proceeds to fund ongoing and ...
financialcontent.com
12/1/2022 Carrick Therapeutics Closes Series C Financing
... developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing. The financing round was supported by existing investors, including ARCH Venture Partners, Rosetta Capital, Lightstone Ventures, Google Ventures, Cambridge Innovation Capital, and Evotec. The Company intends to use the proceeds to fund ongoing and ...
Yahoo News
11/22/2022 FogPharma Nets $178M Series D to Tackle Tough Targets
... potential to become a new treatment option for more than 1 million patients with a broad range of cancers. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts ...
Inside Precision Medicine
11/22/2022 FogPharma Raises $178M in Series D Financing
FogPharma , a Cambridge, MA-based biopharmaceutical company, raised $178M in Series D funding. The round includes new investors ARCH Venture Partners, Milky Way Investments, Fidelity Management & Research Company, and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, T. Rowe Price Associates, Invus, Farallon Capital Management, HBM Healthcare Investments ...
finsmes.com
11/21/2022 FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers | Business Wire
... vast majority of therapeutic targets, including those previously considered ‚Auundruggable,‚Au today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts ...
Business Wire
11/21/2022 FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
... β-catenin inhibitor with potential applicability to significant cancer patient populations, expected to enter clinical development in mid-2023 - The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company - Rick Klausner, M.D., joins board of directors; Founder and CEO Gregory Verdine, Ph.D., appointed ...
pharmaceuticaldaily.com
11/21/2022 FogPharma raises $178M to target cancer
U.S biotech company FogPharma has announced a $178 million series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc ...
labiotech.eu
11/2/2022 Human Immunology Biosciences Launches With $120M
2 Shares Email Facebook Twitter LinkedIn Human Immunology Biosciences , a clinical-stage biotech company, announced on Tuesday it emerged from stealth armed with $120 million. The company was developed by Monograph Capital and ARCH Venture Partners . It was started in 2021, per Crunchbase data. The San Francisco-based company is ...
crunchbase.com
11/1/2022 Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing
HI-Bio is developing precision therapies for patients with immune-mediated diseases Company launches with multiple clinical-stage programs and a robust translational toolkit with potential to address multiple diseases with high unmet medical needs Company funded by ARCH Venture Partners, Monograph Capital, Jeito Capital and others SOUTH SAN FRANCISCO ...
PR Newswire
11/1/2022 Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing
... launches with multiple clinical-stage programs and a robust translational toolkit with potential to address multiple diseases with high unmet medical needs Company funded by ARCH Venture Partners, Monograph Capital, Jeito Capital and others SOUTH SAN FRANCISCO, Nov. 1, 2022 /PRNewswire/ -- Human Immunology Biosciences (HI-Bio‚N¢), a clinical-stage ...
Yahoo News
11/1/2022 Jeito Capital becomes a significant investor in HI-Bio, a
Jeito Capital becomes a significant invest or in HI-Bio , a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company ...
Globe Newswire
11/1/2022 Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
Jeito Capital Jeito Capital becomes a significant invest or in HI-Bio , a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage ...
Yahoo News
11/1/2022 Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph CapitalHI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted ...
indonesiatribune.com
11/1/2022 Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
... HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph CapitalHI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated ...
philippinesnewsgazette.com
11/1/2022 Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
... HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph CapitalHI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated ...
aseantribune.com
11/1/2022 Human Immunology Biosciences launches with $120M
Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. The company was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family ...
labiotech.eu
11/1/2022 Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
... HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph CapitalHI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated ...
thailandnewsgazette.com
10/24/2022 Gene Therapy Pioneers Share Genome Editing Insights at Chardan Conference
... a very passionate urgent approach to how we operated as a company,‚Au said Maraganore, who remains busy in biotech as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, and an Executive Partner at RTW Investments. ‚AuWe were innovation pioneers together. We all had a ...
genengnews.com
10/18/2022 Venture Capital: Under-The -Radar Oncology Start-up Treeline Biosciences Nabs $261M
... Aos Health Care Strategic Growth Fund II, a fund dedicated to investing in high-growth health care-related companies. Other investors included Rock Springs Capital, ARCH Venture Partners, GV, OrbiMed, Access Industries, funds and accounts advised by T. Rowe Price Associates, Inc., Ajax Health/Zeus, Casdin Capital and Aisling Capital ...
dailyalts.com
10/17/2022 Stealth Biotech Startup Treeline Biosciences Raises $261M
... has raised around $473 million in total, according to STAT News‚Ao reporting on SEC filings. Investors include Rock Springs Capital , OrbiMed , Access Industries and ARCH Venture Partners . Despite the healthy influx of funding, Treeline Biosciences has yet to announce any solid drug candidate, but does refer to itself as ...
crunchbase.com
10/14/2022 H|T: The Healthtech Times – Can a hackathon build ArriveCan for less than $54 million?
... dementias, anxiety and depression. Seattle-based Rippl Care is seeking to change this. The startup just closed a $32 million seed funding round led by ARCH Venture Partners and General Catalyst. Subscribe to The Healthtech Times Don‚Aot forget to subscribe to The Healthtech Times using the form below to ...
betakit.com
10/13/2022 InnovationRx: Declining VC Investment In Digital Health; Plus: Long Covid's Impact
... in the third quarter, having invested in seven new rounds. It was followed by Lightspeed Venture partners, which backed five deals, and Transformation Capital and ARCH Venture Partners, each involved in 4 digital health deals. Stopping The Uganda Ebola Outbreak Now Should Be A Global Priority © Provided by Forbes Getty ...
MSN
10/12/2022 InnovationRx: Declining VC Investment In Digital Health; Plus: Long Covid's Impact
... in the third quarter, having invested in seven new rounds. It was followed by Lightspeed Venture partners, which backed five deals, and Transformation Capital and ARCH Venture Partners, each involved in 4 digital health deals. Stopping The Uganda Ebola Outbreak Now Should Be A Global Priority Uganda is facing yet ...
Forbes
10/8/2022 Neumora Therapeutics Announces $112 Million Series B Financing | Business & Finance | tullahomanews.com
... Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund (ADG), Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other undisclosed investors. The funding will support the advancement ...
tullahomanews.com